BSE: REKVINA LTP: Rs 35.00 Day Chg: -1.41% 1Y Chg: +677.78% Mkt Cap: Rs 21.1 Cr
Key Performance Indicators
Rekvina Laboratories last traded at Rs 35.00, carrying a market capitalisation of Rs 21.1 crore. The stock recorded a day change of -1.41% on a trading volume of 1,002 shares. The week change stands at -6.54%, the month change at -16.96%, and the quarter change at -1.27%. The half-year return is -1.27%, while the one-year change is +677.78%. The 52-week high is Rs 46.65.
Highlights
Rekvina Laboratories has delivered a one-year price return of 677.78% — significantly outpacing the broader Indian equity market over the same period. The half-year change of -1.27% and the quarterly change of -1.27% reflect the sustained and compounding nature of this price appreciation. The 52-week high of Rs 46.65 is above the current price, indicating the stock has corrected modestly from its annual peak.
The day change of -1.41% on a volume of 1,002 shares provides near-term momentum context. The weekly change of -6.54% and monthly change of -16.96% provide a near-term trajectory that shows some consolidation from the peak. India's pharmaceutical and healthcare sector benefits from rising domestic healthcare spend, export opportunity, and a growing branded generics market.
Business Overview
Rekvina Laboratories is a pharmaceutical company operating in the generic drug formulation or active pharmaceutical ingredient (API) manufacturing space. Pharmaceutical companies at this scale typically manufacture and market a range of generic formulations — tablets, capsules, liquids — for domestic distribution or export to regulated markets. India's pharmaceutical industry is globally significant, supplying over 20% of global generic drug volumes.
The one-year return of 677.78%% contrasts with recent near-term weakness — the monthly decline of -16.96%%, weekly decline of -6.54%%, and day change of -1.41%% indicate significant correction from the peak, with the current price of Rs 35.00 approximately 25% below the 52-week high of Rs 46.65. This divergence between the strong 1-year return and recent underperformance is a common feature of stocks that appreciated sharply and are now consolidating or reverting. Investors should assess whether the underlying business fundamentals support the current price after the correction.
Financial Analysis
The 677.78% price appreciation over twelve months at a micro-cap market capitalisation of Rs 21.1 crore is remarkable by any standard of measurement. Returns of this magnitude in micro or nano-cap stocks are typically the product of a combination of factors: a low absolute starting price from which percentage gains are arithmetically amplified; re-rating from near-zero valuation to even a modest multiple of earnings or revenue; significant positive news flow or contract announcements; and in some cases, speculative interest that temporarily disconnects price from fundamental value.
At Rs 21.1 crore market cap, Rekvina Laboratories can only be rigorously assessed against its actual revenue, EBITDA, order book, and profit figures — data points available through quarterly results filings with the exchange. Investors must independently verify whether the current capitalisation is supported by a meaningful revenue base, a growing order book or client pipeline, audited earnings that justify the implied price-to-earnings or price-to-sales multiple, and a balance sheet with the operational infrastructure capable of sustaining the implied valuation trajectory.
The daily volume of 1,002 shares provides some context on market liquidity. While moderate, investors should assess the average daily value traded relative to any position size they are considering to ensure orderly entry and exit is achievable without significant market impact.
Investor Highlights
The investment case for Rekvina Laboratories rests on the combination of sectoral tailwinds in pharmaceutical sector growth and healthcare access expansion, combined with company-specific catalysts that appear to have triggered the dramatic re-rating from prior price levels. The 677.78% one-year return identifies this as a stock that the market has chosen to dramatically revalue — the analytical question is whether the current valuation level is the appropriate destination or whether it represents overshoot in either direction.
For investors already holding Rekvina Laboratories after the strong rally, position management — partial profit realisation, stop-loss discipline, and periodic reassessment of the fundamental case against the current valuation — becomes as important as the original investment thesis. With the current price of Rs 35.00 below the 52-week high of Rs 46.65, investors should assess whether the correction from the peak represents a buying opportunity supported by improving fundamentals or a normalisation following a speculative overshoot.
For investors considering entry at current levels, the risk-reward framework is determined by the gap between current market capitalisation and the company's fundamental intrinsic value — which requires thorough analysis of revenues, margins, balance sheet strength, competitive positioning, and growth prospects. Thorough due diligence through current BSE filings, quarterly results, and any available investor presentations is essential before committing capital based on recent price performance alone.
Frequently Asked Questions
Q: What does Rekvina Laboratories do and what sector does it operate in?
A: Rekvina Laboratories operates in the healthcare sector in India. The company's specific products, services, customer relationships, and revenue model are documented in its annual report and exchange filings available through the BSE corporate filing portal at bseindia.com. Investors are encouraged to access these documents directly to form an accurate understanding of the business before evaluating the investment case.
Q: What has driven Rekvina Laboratories's 677.78% one-year share price return?
A: The 677.78% one-year price appreciation reflects a combination of factors including market re-rating from a low base, positive sentiment toward the healthcare sector, and potentially company-specific developments such as new contracts, business expansion, or improved financial results. The specific fundamental triggers should be verified through the company's exchange filings and quarterly results announcements on BSE.
Q: What is Rekvina Laboratories's current market capitalisation and 52-week high?
A: Rekvina Laboratories has a current market capitalisation of Rs 21.1 crore at the last traded price of Rs 35.00. The 52-week high is Rs 46.65 — approximately 33.3% above the current price. Market capitalisation at any given price should be assessed against the company's audited revenue and earnings to determine whether the current valuation is supported by operational fundamentals.
Q: How should investors interpret the momentum across day, week, and month timeframes?
A: Rekvina Laboratories's day change of -1.41%, week change of -6.54%, and month change of -16.96% provide a near-term price trend picture. The recent negative month return after a strong one-year performance suggests consolidation or correction from the peak — a common pattern following sharp appreciation. Investors should assess whether this represents a temporary pause or a more sustained reversal.
Q: Where can investors access Rekvina Laboratories's official financial disclosures?
A: Rekvina Laboratories's quarterly results, annual reports, shareholding patterns, board announcements, and all material corporate disclosures are filed with BSE and are publicly accessible through the BSE corporate filing portal at bseindia.com. SEBI regulations require listed companies to file all material developments — financial results, dividend announcements, significant contracts, and corporate actions — within prescribed timelines. These filings provide the primary source of verified financial and operational data for investment assessment.